ResMed stock gains on RBC upgrade and new institutional buying

ResMed Inc. stock (ISIN AU000000RMD6) last closed at USD 225.35 on Nasdaq on September 18, 2026, leaving the shares about 6.7 percent below the USD 241.69 consensus analyst price target cited in recent coverage. As of September 19, 2026, the key fresh catalyst for ResMed stock is an upgrade to Outperform with a higher price target alongside visible new institutional buying.

Analyst upgrade lifts price target

According to Yahoo Finance on September 19, 2026, a research firm upgraded ResMed Inc. stock to Outperform from Sector Perform on September 15, 2026 and raised its price target to USD 262 from USD 244, citing the company’s market leadership in obstructive sleep apnea devices as a driver of long-term value creation. This represents a 7.4 percent increase in the price objective and places the new target about 16.3 percent above the latest Nasdaq closing price of USD 225.35 as of September 18, 2026.

As MarketBeat reported on September 19, 2026, ResMed currently carries an average analyst rating of Hold, based on seven Buy ratings and nine Hold ratings, with a consensus price target of USD 241.69. With the shares at USD 225.35 on Nasdaq at the close on September 18, 2026, this consensus implies potential upside of roughly 7.3 percent if the stock were to reach the average target.

Earnings beat and dividend increase underpin fundamentals

Fundamentals remain an important anchor for investors. According to MarketBeat, ResMed most recently reported quarterly earnings of USD 2.95 per share, beating consensus expectations, on revenue of USD 1.46 billion for that quarter. The same overview notes that revenue grew 8.6 percent year over year in this reporting period, signalling solid top-line expansion alongside the earnings beat.

In addition, the company raised its quarterly dividend to USD 0.66 per share in the latest period, according to MarketBeat, which represents a higher cash return to shareholders compared with the previous payout. For income-oriented investors, the combination of mid to high single-digit revenue growth and a rising dividend is an important part of the investment case, even as the stock still trades below both the new USD 262 target and the USD 241.69 consensus level.

New institutional investment and risk considerations

The latest news flow also highlights renewed institutional interest. As MarketBeat reported on September 19, 2026, Nykredit A S acquired 338,702 ResMed shares during the second quarter, a position worth approximately USD 66 million. The same filing note points out that institutional investors now own about 54.98 percent of ResMed’s shares, underlining that the stock is widely held by professional investors who are positioning for ongoing growth.

Analyst commentary also touches on competitive pressures and valuation risk. The upgrade to Outperform referenced by Yahoo Finance acknowledges rising competition in sleep apnea and respiratory care devices, but argues that ResMed’s leadership position and product ecosystem support continued growth. At the same time, the Hold consensus rating highlighted by MarketBeat indicates that several analysts are cautious, balancing the company’s earnings strength and dividend growth against valuation and competitive risks.

Stock trades below consensus target

Per Nasdaq-linked data aggregated by MarketBeat, ResMed stock closed at USD 225.35 on Nasdaq on September 18, 2026, down 1.34 percent from the prior close, with a modest further move to USD 225.24 in extended trading that evening. The same overview positions this closing price against the USD 241.69 consensus price target, leaving the shares trading about 6.7 percent below that average objective as of September 18, 2026.

More news and analyses on ResMed Inc. stock